FLT3 and acute myeloid leukemia: The presence of CEBPA mutations identifies a group of patients with a better prognosis within the young high-risk CN-AML group (patients with FLT3-ITD and/or wild-type (wt) NPM1) (Marcucci et al, 2008b).